Clinical Trials Logo
  1. Home
  2. Small Cell Lung Carcinoma
  3. NCT03735095

Endobronchial Ultrasound Guided Interstitial Photodynamic Therapy in Treating Patients With Locally Advanced Lung Cancer

Small Cell Lung Carcinoma Clinical Trial

Official title:
Endobronchial Ultrasound Transbronchial Needle Guided Interstitial Photodynamic Therapy for Palliation of Locally Advanced Lung Cancer and Advanced Cancers Obstructing the Airway -Phase I/II

Clinical Trial Summary

This Phase I/Il studies the side effects of endobronchial ultrasound guided interstitial photodynamic therapy work in treating patients with lung cancer that has spread to nearby tissues or lymph nodes. Photodynamic therapy consists of injecting a light sensitive drug called a photosensitizer, such as porfimer sodium, into the vein, waiting for it to accumulate in the tumor, and then activating it with a red laser light. Giving photodynamic therapy with Porfimer sodium may reduce the tumor size in patients with lung cancer.

Clinical Trial Description

PRIMARY OBJECTIVES PHASE 1: I. To evaluate the safety and potential efficacy of endobronchial ultrasound with transbronchial needle (EBUS-TBN) guided interstitial photodynamic therapy (EBUS-TBN I-PDT) and/or I-PDT and/or photodynamic therapy (PDT) in patients with malignant airway obstructions using porfimer sodium as a photosensitizer. PRIMARY OBJECTIVE Phase II - I. To assess the tumor response to treatment. - II To observe changes in well being SECONDARY OBJECTIVES: - I. To evaluate local progression-free survival (PFS). - II.To compare the treatment planning in DOSIE™ with the plan generated in COMSOL™ - COHORT A ONLY - III. To measure changes in tumor pO2, optical properties, and irradiance and fluence in relationship to response EXPLORATORY OBJECTIVES: I. Examine porfimer sodium retention in the target tumor tissue. II. Examine the relationship between immune biomarkers and response. OUTLINE: Patients receive Porfimer sodium intravenously (IV) over 20 minutes 2-4 hours prior to the delivery of I-PDT. Patients then undergo EBUS-TBN guided I-PDT over 30-45 minutes. After completion of study treatment, patients are followed up at 4, 8, 12, and 24 weeks. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03735095
Study type Interventional
Source Roswell Park Cancer Institute
Contact
Status Recruiting
Phase Phase 1/Phase 2
Start date February 12, 2020
Completion date February 12, 2030
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05882058 - DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers Phase 2
Terminated NCT03963414 - A Study of Durvalumab Plus Tremelimumab With Chemotherapy in Untreated ES-SCLC Phase 1
Active, not recruiting NCT04358237 - Lurbinectedin (PM01183) Combined With Pembrolizumab in Small Cell Lung Cancer. Phase 1/Phase 2
Not yet recruiting NCT06419179 - Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC) Phase 2
Completed NCT02874664 - A Study of Rovalpituzumab Tesirine to Study Cardiac Ventricular Repolarization in Subjects With Small Cell Lung Cancer Phase 1
Completed NCT02397733 - Memory Preservation of Prophylactic Cranial Irradiation With Hippocampal Avoidance (PREMER-TRIAL) N/A
Recruiting NCT01977235 - Two Different Dosages of Irinotecan Combined With Cisplatin Scheme in Extensive Disease-Small Cell Lung Cancer Phase 2
Completed NCT00759824 - A Phase II Study of Doxorubicin, Cyclophosphamide and Vindesine With Valproic Acid in Patients With Refractory or Relapsing Small Cell Lung Cancer After Platinum Derivatives and Etoposide Phase 2
Active, not recruiting NCT03568097 - Immunotherapy in Combination With Chemotherapy in Small-cell Lung Cancer Phase 2
Withdrawn NCT02876081 - Phase II Study of Afatinib as Third- or Further-line Treatment for Patients With Stage IV Bronchial Adenocarcinoma, Harboring Wild-type EGFR, Expressing the Neurotensin - Neurotensin Receptor Complex Phase 2
Recruiting NCT06247605 - A Phase IIII Study of AL8326 in Small Cell Lung Cancer Phase 3
Recruiting NCT04996771 - Surufatinib Combined With Chemotherapy Plus Toripalimab or Not in the Treatment of Small Cell Lung Cancer Phase 1/Phase 2
Terminated NCT03662074 - Subsequent Line Gemcitabine and Nivolumab in Treating Participants With Metastatic Small Cell Lung Cancer Phase 2
Completed NCT03232593 - A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s)
Completed NCT01941316 - Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients Phase 1/Phase 2
Terminated NCT01574300 - Collaborative Advanced Stage Tissue Lung Cancer (CASTLE) Network
Recruiting NCT06131840 - A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors Phase 1
Recruiting NCT05683977 - A French Real-life Study: EvaluatioN of durvALumab Utilization and Effectiveness for First Line Extensive Stage Small Cell Lung Cancer.
Recruiting NCT04620837 - Tislelizumab in Combination With Anlotinib With ES-SCLC as Maintenance Therapy After First Line Chemotherapy Phase 2
Recruiting NCT05329623 - A Phase 1 Study to Evaluate the Pharmacokinetics of JDQ443 in Participants With Hepatic Impairment Compared to Matched Healthy Control Participants. Phase 1